prevalence, and co-morbidities); use of health services; gaps in services and recommended improvements; and impacts of neurological conditions now and projected over the next 20 years (including economic cost). A comprehensive report of the study findings will be published in 2014.
Information on the burden of neurological conditions is limited or unavailable
The WHO's Global Burden of Disease report (2006) and CIHI's report on the Burden of Neurological Diseases, Disorders, and Injuries in Canada (2007) both found that while the burden of neurological disorders in Canada is high (over 10% of total disability), complete information on the burden of these conditions is unavailable. 1,2 Indeed, for CIHI's report, only 6 out of 11 neurological conditions examined had estimates of disability burden.
Patient registries are a key source of data to assess the burden of neurological conditions
A patient registry can be defined as an observational cohort study of real-world clinical practice related to a disease condition or procedure/therapy, without a study-mandated treatment. With the ability to securely catalogue and track many patients across large geographical areas, registries can provide epidemiological data and fill gaps in medical evidence. 4 In addition to tracking disease burden and therapeutic effectiveness, registries may be useful for tracking the use of medical therapies, performance measurement for the purpose of quality improvement, evaluating the "real world" effectiveness of medical therapies in practice outside the highly controlled conditions of clinical trials, identifying relationships between risk factors and disease outcomes, and evaluating access to care. Despite the utility of registries little guidance is available for investigators and stakeholders on the quality of information derived from these data sources. 4 The WHO's World Health Report identified five core competencies for long term patient care.
1 One of these five core competencies was the development of information and communication technologies including registries to ensure continuity of care.
As Canada's healthcare system faces multiple stressors over the next 20 years including increasing costs, mismatches between human resource supply and demand, and an aging population, solutions to address the increasing burden of neurological disease must be identified urgently. The first step towards this goal is to improve the available information on neurological disease burden in Canada.
The key to successful national neurological registries is to develop consensus guidelines and a toolkit that will guide registry leaders in their development to ensure comprehensive, systematic, and meaningful collection of data.
Patient registries present an important opportunity to improve the information available in Canada on neurological disease burden. However, statistics collected from patient registries will only be meaningful if the registries are implemented consistently so the data collected can be compiled and compared.
A significant need exists for comprehensive guidelines for registry development (including online registries) and implementation within neurological disease in Canada. Varying provincial privacy regulations and research ethics review board (REB) perceptions result in logistical and financial obstacles to multi-regional and national registry implementation and operation within Canada. The development of consensus guidelines targeting best practices and identified obstacles will facilitate current registry operations and the design and implementation of new registries.
METHODS
To inform the guideline development process we performed a comprehensive exploratory literature review. Patient and caregiver focus groups were concomitantly performed to ensure the relevance of the guidelines to the target population.
Literature Review
A literature review aiming to identify all patient registryrelated literature was performed using search terms such as register, registry and registries. The search strategy (see Appendix A) was developed in consultation with a research librarian and included the following databases: Medline, EMBASE, Pubmed, Cochrane Central, Cochrane SR, PsycINFO, ABI Inform, BIOSIS Previews, and PAIS (Public Affairs Information Service). Figure 1 outlines the flow of article identification and screening. We identified 19,002 abstracts with 6,435 remaining after duplicates and non-English articles were removed. The first reviewer excluded 2, 238 abstracts. Included abstracts were then reviewed by a second reviewer and a further 3,787 abstracts were excluded. In total 410 full-text articles were reviewed. Relevant aspects of this literature review are outlined in this document and served to inform the guideline development process.
Guideline Development
This guideline document was developed through an iterative process involving multiple stakeholders. In April of 2012, three patient and caregiver focus groups were held at the University of Calgary. The methods and results of the focus groups are published elsewhere.
Second, the results of the literature review and the focus groups were presented at a preliminary meeting of registry and disease experts held in Calgary in May 2012. At this meeting, the overall climate for registry development in Canada was discussed and work teams were formed to brainstorm and develop the sections of this document. Finally, a second meeting was held in Calgary in September 2012 with work team members, and additional registry, disease experts, and other stakeholders (e.g. ethics, legal, privacy) to finalize the content of this guidelines document.
Toolkit Development
Accompanying this guideline document is a toolkit of resources conceived to assist in the design and implementation of new neurological registries in Canada. This toolkit was assembled from a variety of existing resources across the entire registry spectrum. The toolkit and the guideline document are intended to be used in concert and it is our sincere hope that it will be a helpful resource. The complete toolkit is available at http://www.canadianregistrynetwork.org.
Overview
This guideline document is organized into three parts consecutively addressing registry design, quality and impact. Each part begins with an executive summary that summarizes key points. More in-depth and supporting information is presented thereafter.
It is our hope that this guideline document and accompanying toolkit will be useful to registry leaders, staff, investigators, patient organizations, governmental agencies, the pharmaceutical and biotechnology industries, and other institutions, groups and individuals with respect to the following:
1. Determining whether a registry is appropriate to address a specific question or series of questions 2. Providing resources to assist in developing the case for a registry 3. Providing a comprehensive framework for registry design (i.e. protocol development, ethics board submission, data collection infrastructure development) 4. Understanding and addressing the importance of quality control and assurance 5. Techniques in validation and interpretation of registry data 6. The importance of the impact of a registry and its measurement THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
